CORE--BIOSAMPLE REPOSITORY

核心--BIOSAMPLE存储库

• 批准号: 7142518
• 负责人: Robert C Young
• 金额: $ 7.21万
• 依托单位: FOX CHASE CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-10 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7142518
• 关键词: biomedical facility; cancer registry /resource; human tissue; tissue resource /registry; biomedical facility; cancer registry /resource; human tissue; tissue resource /registry

Translational research requires access to appropriately consented and well-characterized human biosamples. Therefore, the Fox Chase Cancer Center (FCCC) established the Biosample Repository Core Facility (BRCF) in 1999/2000 to support this research. The BRCF is a CAP accreditation and CLIA-approved Facility that has two major functions: 1) BRCF staff identifies participants, administers informed consent for blood and tissue use, and collects blood samples and information on personal and family histories of cancer, clinical intervention, clinical outcomes, and lifestyle factors for use in research, and 2) BRCF staff processes and houses human biospecimens obtained through investigator-initiated studies. The FCCC has many funded research Programs which require access to biospecimens from large cohorts of properly consented individuals affected and unaffected with cancer. Programs include: i) clinical studies to assess genetic susceptibility in cancer prone-kindreds, ii) large scale genotyping studies to identify genetic modifiers of cancer risk, iii) pharmacogenomic studies to identify drug response and drug toxicity markers, iv) hormone and immune response studies to determine the role of psychological stress and breast cancer risk, v) smoking cessation studies using genetic modifiers to assess behavioral response, vi) hormone and genotype studies to predict cancer risks, vii) identifying plasma membrane proteins that are selectively expressed in lung or prostate cancer to identify new targets for the development of additional therapeutic monoclonal antibodies, and viii) studies of early detection of cancer by genetic, epigenetic, and proteomic approaches. The BRCF provides a centralized service for accrual, consenting, processing, banking, and/or distribution of human blood samples (e.g., whole blood, plasma, serum, platelet-rich plasma, platelet homogenates, red blood cells, leukocytes, lymphoblastoid cell lines, and DNA) and cancer history data to be utilized in genetic-, epigenetic-, and proteomic-related research. The BRCF currently houses more than 300,000 human biosamples and has served 28 (26 peer-reviewed funded) Fox Chase investigators across 12 Programs and the three Divisions since its inception at the time of previous Core renewal. Ninety-six percent (96%) of the BRCF's use is by peer-reviewed funded investigators.

翻译研究需要访问适当的同意和良好的特征 人类生物样本。因此，Fox Chase癌症中心（FCCC）建立了生物样品 存储库核心设施（BRCF）于1999/2000年支持这项研究。 BRCF是帽子 认证和CLIA批准的设施，具有两个主要功能：1）BRCF员工确定 参与者，管理知情的血液和组织使用同意，并收集有关癌症的个人和家庭历史，临床干预，临床结果以及研究中使用的生活方式因素的信息，以及2）BRCF员工流程并容纳了通过研究人员推动的研究获得的人类生物素质。 FCCC有许多资助的研究计划，这些计划需要从大量适当同意的人群中获得生物测量，并未受到癌症的影响。 Programs include: i) clinical studies to assess genetic susceptibility in cancer prone-kindreds, ii) large scale genotyping studies to identify genetic modifiers of cancer risk, iii) pharmacogenomic studies to identify drug response and drug toxicity markers, iv) hormone and immune response studies to determine the role of psychological stress and breast cancer risk, v) smoking cessation studies using genetic modifiers to assess behavioral response, vi) hormone and预测癌症风险的基因型研究，vii）鉴定在肺或前列腺癌中选择性表达的质膜蛋白，以鉴定出开发其他治疗性单克隆抗体的新靶标，以及通过遗传，表观遗传学，遗传学和蛋白质组学方法来早期检测到癌症的早期检测。 BRCF为人类血液样本（例如全血，血浆，血清，血清，富含血小板的血浆，血小板匀浆，红细胞，白细胞，白细胞细胞，淋巴结细胞系和淋巴样细胞系和癌症史的概述 - 属于epigencentic centenic-eelicentimentic centenic centenic centenic centenic-eelicentimentimentimentimentic centenic centenic centenic centenic centenic---------- BRCF目前拥有300,000多个人类生物样本，并为28个（由同行评审的资助）提供了28个计划，自从上次核心续订时就成立了12个计划和三个部门。 BRCF使用的百分之九十六（96％）是通过同行评审的资助研究人员。